Is platelet-lymphocyte ratio (PLR) a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence-free survival in patients with gastric cancer?
ABSTRACT Introduction: Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in oncology patients. There are no accurate risk assessment tools to predict venous thromboembolism (VTE). Circulating tumor cells (CTCs), circulating tumor microemboli (CTM), and high platelet-lymphocyte ratio (PLR) may predispose to VTE. Objective: To evaluate correlations of CTCs, CTM,...
